The HBV MTCT rates were stratified by sociodemographic characteristics and the compliance group. Pregnant women from 31 provinces were divided into the following three regions according to the addresses of hospitals they visited to analyze regional disparities: eastern China, central China and western China. Compliance refers to patients compliance with the whole process of HBV mother-to-child prevention management strictly by the following two situations: (1) for patients with HBV DNA 200,000 IU ml -1 (defined as a high-risk group), antiviral therapy was initiated at 24-28 weeks gestation, and their newborn completed immunization (including birth dose of HepB and HBIG within 12 h, and the completion of three doses of HepB); (2) for patients with HBV DNA <200,000 IU ml -1 (defined as a low-risk group), their newborns were immunized (including birth dose of HepB and HBIG) within 12 h and completed three doses of HepB. The data are presented as rates (points) and 95% CIs (error bars).
